Back to top
more

GlycoMimetics (GLYC)

(Delayed Data from NSDQ)

$2.26 USD

2.26
763,637

-0.15 (-6.04%)

Updated Apr 15, 2024 04:00 PM ET

After-Market: $2.26 +0.01 (0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (153 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for GLYC

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

GlycoMimetics, Inc. [GLYC]

Reports for Purchase

Showing records 1 - 20 ( 156 total )

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 1

01/31/2024

Daily Note

Pages: 114

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 2

01/30/2024

Daily Note

Pages: 115

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 3

01/04/2024

Daily Note

Pages: 3

Positive Initial Results From Phase 1a Healthy Volunteer Study of GMI-1687

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 4

01/03/2024

Daily Note

Pages: 4

Partner in China Completes Enrollment in Phase 3 Bridging Study of Uproleselan in r/r AML

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 5

12/11/2023

Daily Note

Pages: 3

Independent Study Presentation at ASH Highlights New Positive Data for Uproleselan

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 6

11/06/2023

Company Report

Pages: 8

3Q23 Results; Phase 3 Data For Uproleselan in R/R AML Projected for 2Q24

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 7

09/06/2023

Daily Note

Pages: 3

First Cohort of Healthy Volunteers Dosed in Phase 1a Study of GMI-1687

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 8

08/03/2023

Company Report

Pages: 8

2Q23 Results; Uproleselan Phase 3 Data Expected 2Q24; GMI-1687 to Enter the Clinic This Quarter

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 9

06/15/2023

Daily Note

Pages: 3

Addition of Time-Based Final Analysis Cleared by FDA For Phase 3 Trial of Uproleselan in r/r AML

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 10

05/04/2023

Company Report

Pages: 8

1Q23 Results; Final OS Events Trigger For Phase 3 Study of Uproleselan in AML on Track for 1H24

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 11

03/30/2023

Company Report

Pages: 8

4Q22 Results; Phase 3 Uproleselan Study Final Event Trigger Expected 1H24

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 12

02/15/2023

Company Report

Pages: 7

IDMC Recommends Phase 3 Study of Uproleselan For r/r AML to Proceed to Planned Final Survival Analysis; Lower PT by $5

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 13

12/13/2022

Company Report

Pages: 8

Data From Uproleselan in AML ISTs at ASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 14

11/09/2022

Company Report

Pages: 8

3Q22 Results; Phase 3 Interim Data IDMC Review Expected by End of 1Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 15

08/03/2022

Company Report

Pages: 8

2Q22 Results; Waiting on Phase 3 Data For Uproleselan in r/r AML; Lower PT by $1

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 16

06/09/2022

Daily Note

Pages: 3

Healthcare Coverage Update - Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 17

04/29/2022

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 18

04/28/2022

Company Report

Pages: 6

1Q22 Results; Uproleselan Pivotal Data Expected Shortly After Mid-2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 19

04/28/2022

Company Report

Pages: 5

1Q2022 Update - Still a Great Buy and a Strong M&A Target - $15 PT

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 5.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 20

04/12/2022

Industry Report

Pages: 3

AACR Presentation Takesways

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 5.00

Research Provided by a Third Party